{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"","title":"Pfizer and Novo Nordisk’s $10bn battle over weight-loss drugs","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/615edd9c0cb78d1a6bda37d9/1776246221046-6e0fce5d-a87f-4da7-90d7-a92716b6713c.jpeg?height=200","description":"

Pharma juggernauts Pfizer and Novo Nordisk are struggling in the obesity drug race.The two companies are searching for their next moneymaker, and that search recently spun out into a ferocious, multibillion-dollar battle for control of biotech start-up Metsera. The FT’s US deals and activism correspondent Oliver Barnes walks through the tussle that’s involved lawsuits, public barbs and political drama.


Clips from CNBC, Pfizer, Yahoo Finance


- - - - - - - - - - - - - - - - - - - - - - - - - - 


For further reading and listening:

Weight-loss wars: $10bn hostile battle pits Pfizer against Novo Nordisk

Pfizer shows hardball mettle needed to win in 2025 M&A

There is only one winner in the Pfizer Novo Nordisk showdown

Ozempic’s unconventional origins


- - - - - - - - - - - - - - - - - - - - - - - - - - 


Attend the FT Global Banking Summit, 2-4 December in London: Enter SAVE20 for a 20% discount, register here.


- - - - - - - - - - - - - - - - - - - - - - - - - - 


Follow Oliver Barnes on X (@mroliverbarnes), or on Bluesky (@mroliverbarnes.bsky.social) Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more.


Read a transcript of this episode on FT.com


","author_name":"Financial Times"}